Last update 07 Nov 2024

Glembatumumab vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Glembatumumab vedotin (USAN), CDX-011, CR-011-ADC
+ [1]
Mechanism
GPNMB modulators(Transmembrane glycoprotein NMB modulators), Tubulin inhibitors
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC39H67N5O7
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N
CAS Registry474645-27-7
View All Structures (2)
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
squamous cell lung carcinomaPhase 2
US
10 Apr 2016
MelanomaPhase 2
US
01 Nov 2014
Triple Negative Breast CancerPhase 2
US
01 Nov 2013
Triple Negative Breast CancerPhase 2
AU
01 Nov 2013
Triple Negative Breast CancerPhase 2
BE
01 Nov 2013
Triple Negative Breast CancerPhase 2
CA
01 Nov 2013
Triple Negative Breast CancerPhase 2
FR
01 Nov 2013
Triple Negative Breast CancerPhase 2
DE
01 Nov 2013
Triple Negative Breast CancerPhase 2
IT
01 Nov 2013
Triple Negative Breast CancerPhase 2
ES
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
13
jjamrxxbif(dmskdxnrvb) = vslpclpkpb wwovqvzfxv (oihxnnryxi, 1.6 - 5.8)
Positive
24 Mar 2021
Not Applicable
13
ypueyqfkyc(nmqmaidsnh) = Adverse events (AE) of any grade seen in 15% of patients were dyspnea, neutropenia, respiratory failure, anemia, >AST/ALT, diarrhea, hypophosphatemia. No AEs were seen at a frequency more than 23%; these were decreased appetite, fatigue, rash, weight loss. The only Grade 5 events were 2 respiratory failure (one partially and one completely attributed to cancer progression). Another Grade 5 event was solely “disease progression”. iayqrzusmm (lfdqsmqqob )
-
29 Jan 2021
Phase 2
37
Pharmacological Study+glembatumumab vedotin
nvfzvwejmd(izwcnawtlb) = flbhpzpsqy jrzhjazkhx (aybaldodqm, vqwvgexhxw - iihvzulieg)
-
21 Aug 2020
Phase 2
35
tliaqcqaiw(qtgbpschqq) = stjwlkbqfl jqiraczbah (brzxljtvgy )
Positive
13 Aug 2020
Phase 2
22
eqfjbyggtf(rnezouosty) = rash bvtjkzuhxv (zwvpsafhtb )
Negative
01 Nov 2019
Phase 2
132
(Glembatumumab Vedotin)
wtxzdxgkqf(zpwtshchrl) = rxmqthprcz chnojimehq (tlrkaqiemw, ojsvtmdtfb - vsrqecpnjq)
-
06 Sep 2019
(Glembatumumab Vedotin and Varlilumab)
wtxzdxgkqf(zpwtshchrl) = dclbpdjtti chnojimehq (tlrkaqiemw, gjlhtrwejk - zswsphdrab)
Phase 2
327
epsbwxuccl(zsmduzqwtr) = mchtnaoofa wvoyatjedv (udqjdscwlc, epkqmccqsv - dekzkyylfu)
-
08 Mar 2019
Phase 2
327
wlggjzfhba(pimwffxmlj) = wxrmqymxrd pctyfnqwii (ecuygzmkhx, 2.8 - 3.5)
Negative
15 Feb 2019
wlggjzfhba(pimwffxmlj) = gfjfhjtfad pctyfnqwii (ecuygzmkhx, 1.6 - 3.2)
Phase 2
22
Pharmacological Study+glembatumumab vedotin
hqxgrjaiuj(vgtsubzewy) = gmnaacnysy wqpmttfwip (wducvixlxr, jgawienjep - htrrfgxwqi)
-
15 Oct 2018
Phase 2
62
wyvmhyniha(txnslgihya) = nvmiscckdq mpqenpdvfb (lreymbkxra )
Positive
30 May 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free